AR066668A1 - PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN ANTI-CONVULSIVE AGENT AND AN ANTI-VIRAL AGENT - Google Patents

PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN ANTI-CONVULSIVE AGENT AND AN ANTI-VIRAL AGENT

Info

Publication number
AR066668A1
AR066668A1 ARP080102159A ARP080102159A AR066668A1 AR 066668 A1 AR066668 A1 AR 066668A1 AR P080102159 A ARP080102159 A AR P080102159A AR P080102159 A ARP080102159 A AR P080102159A AR 066668 A1 AR066668 A1 AR 066668A1
Authority
AR
Argentina
Prior art keywords
agent
pharmaceutical composition
combination
convulsive
gabapentin
Prior art date
Application number
ARP080102159A
Other languages
Spanish (es)
Inventor
Armenta Maria Elena Garcia
Ochoa Victor Guillermo Alvarez
Murillo Josefina Santos
Original Assignee
World Trade Imp Export Wtie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40032120&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR066668(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by World Trade Imp Export Wtie Ag filed Critical World Trade Imp Export Wtie Ag
Publication of AR066668A1 publication Critical patent/AR066668A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicacion 1: Composicion farmacéutica caracterizada por estar compuesta por la combinacion sinérgica de un agente anticonvulsivo, tal como lo es el principio activo: Gabapentina y un agente antiviral, tal como lo es el principio activoAciclovir, los cuales se encuentran presentes en la formulacion en un rango de concentracion de 300.0 mg. a 900.0 mg. para la Gabapentina y de 200.0 mg. a 800.0 mg. para el Aciclovir, además de excipientes farmacéuticamente aceptables; mismos que seencuentran formulados en una sola unidad de dosificacion para ser administrada por vía oral; la cual está indicada para la prevencion y/o tratamiento de la Neuralgia Post-herpética.Claim 1: Pharmaceutical composition characterized by being composed of the synergistic combination of an anticonvulsant agent, such as the active ingredient: Gabapentin and an antiviral agent, such as the active ingredient Acyclovir, which are present in the formulation in a concentration range of 300.0 mg. at 900.0 mg for Gabapentin and 200.0 mg. at 800.0 mg for Acyclovir, in addition to pharmaceutically acceptable excipients; same that are formulated in a single dosage unit to be administered orally; which is indicated for the prevention and / or treatment of Post-herpetic Neuralgia.

ARP080102159A 2007-05-21 2008-05-21 PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN ANTI-CONVULSIVE AGENT AND AN ANTI-VIRAL AGENT AR066668A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2007006093A MX2007006093A (en) 2007-05-21 2007-05-21 Pharmaceutical composition combining an anticonvulsant agent and an antiviral agent.
PCT/MX2008/000061 WO2008143490A1 (en) 2007-05-21 2008-05-19 Pharmaceutical composition combining an anticonvulsant agent and an antiviral agent

Publications (1)

Publication Number Publication Date
AR066668A1 true AR066668A1 (en) 2009-09-02

Family

ID=40032120

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102159A AR066668A1 (en) 2007-05-21 2008-05-21 PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN ANTI-CONVULSIVE AGENT AND AN ANTI-VIRAL AGENT

Country Status (7)

Country Link
AR (1) AR066668A1 (en)
CL (1) CL2008001476A1 (en)
CO (1) CO6241103A2 (en)
MX (1) MX2007006093A (en)
PE (1) PE20090292A1 (en)
UY (1) UY31095A1 (en)
WO (1) WO2008143490A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1093366E (en) * 1998-07-09 2005-02-28 Warner Lambert Co PHARMACEUTICAL COMPOSITIONS CONTAINING GABA ANALOGS AND AN ANTIBIRAL AGENT FOR THE TREATMENT OF HERPES ZOSTER

Also Published As

Publication number Publication date
CL2008001476A1 (en) 2008-07-11
UY31095A1 (en) 2008-11-28
WO2008143490A1 (en) 2008-11-27
CO6241103A2 (en) 2011-01-20
MX2007006093A (en) 2009-02-25
PE20090292A1 (en) 2009-04-04

Similar Documents

Publication Publication Date Title
ES2916649T1 (en) Compositions and uses for the treatment of multiple sclerosis
ES2553742T3 (en) Pharmaceutical dosage form comprising 6'-fluor- (N-methyl- or N, N-dimethyl) -4-phenyl-4 ', 9'-dihydro-3'H-spiro [cyclohexane-1,1'-pyran [3,4, b] indole] -4-amine
AR068820A1 (en) PHARMACEUTICAL COMPOSITION UNDERSTANDING THE COMBINATION OF VENOTONIC AGENTS AND VASOPROTECTORS FOR THE TREATMENT OF CHRONIC VENOUS INSUFFICIENCY AND USE
AR048705A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SEXUAL DISORDERS II
AR054064A1 (en) COMPOSITION WITH ACTIVE PHARMACEUTICAL INGREDIENT BASED ON CANABINOID FOR IMPROVED DOSE FORMS
MX2009003372A (en) Non-mucoadhesive film dosage forms.
WO2009051840A3 (en) Compositions and methods for reducing hepatotoxicity associated with drug administration
AR066666A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN NON-STEROID ANTI-INFLAMMATORY AGENT AND AN ANTI-CONVULSIVING AGENT
AR061233A1 (en) FORMULATION OF PROLONGED LIBERATION OF NALTREXONA
CO6220945A2 (en) USE OF A COMPOSITION THAT INCLUDES FORMOTEROL AND DIPROPIANATE OF BECLOMETASONE FOR THE PREVENTION AND / OR TREATMENT OF AN EXAMERATION OF ASTHMA
PE20130147A1 (en) PHARMACEUTICAL COMBINATION OF THEOBROMINE AND A NON-OPIOID ANTITUSSIVE AGENT
ES2526359T3 (en) Oral galenic formulation comprising ketorolac and B vitamins, in which vitamin B6 is in an external layer separated from the rest of active ingredients
CO2020001887A2 (en) Synergistic pharmaceutical combination of the active enantiomer s-ketorolac and gabapentin for the treatment of neuropathic pain
CO6270220A2 (en) PHARMACEUTICAL COMPOSITIONS UNDERSTANDING THE COMBINATION OF A NON-STEROID ANTIINFLAMOTORY AGENT AND AN INHIBITING AGENT OF THE XANTINO OXIDASE USEFUL FOR THE CONTROL AND TREATMENT OF THE DROP DROPPED ARTHRITIS AND RELATED DISEASES
MX2013001279A (en) Pharmaceutical composition with a selective enzyme phosphodiesterase inhibitor in an oral gel form.
CO6321156A2 (en) PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF SEXUAL TRANSMISSION INFECTIONS
AR066668A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN ANTI-CONVULSIVE AGENT AND AN ANTI-VIRAL AGENT
AR067320A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN ANTIMICROBIAL AGENT AND AN ANTIOXIDANT AGENT FOR THE TREATMENT OF URINARY INFECTIONS
AR066667A1 (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE COMBINATION OF A HYDROGEN DERIVATIVE LIPSTATINE AGENT AND AN HMG COA REDUCTASA INHIBITING AGENT
AR067861A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN ANTI-CONVULSIVELY AGENT AND A BENZODIAZEPINIC AGENT, INDICATED FOR THE CONTROL AND TREATMENT OF CONVULSIVE DISORDERS AND EPILEPTIC SYNDROMES
AR048355A1 (en) ASSOCIATION BETWEEN A HETEROCICLICAL COMPOUND AND AN ANTIOXIDANT AGENT AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR067700A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING THE COMBINATION OF AN ANTIMICROBIAL AGENT AND A SELECTIVE INHIBITING AGENT OF THE ENCEPHALINE ENZYME INDICATED FOR THE CONTOL AND TREATMENT OF THE ACUTE BACTERIAL DIARRHEA
CO6260067A2 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING THE COMBINATION OF ACETACINE METOCARBAMOL AND DIACEREIN USEFUL IN THE TREATMENT OF ARTHRITIS AND REUMATOID T RELATED DISEASES
AR067465A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF A BENZISOXAZOLIC DERIVATIVE AGENT AND A BENZODIAZEPINIC AGENT
AR063697A1 (en) DOSAGE OF BIFERUNOX TO TREAT SCHIZOPHRENIA

Legal Events

Date Code Title Description
FB Suspension of granting procedure